J
Joon S. Lee
Researcher at University of Pittsburgh
Publications - 76
Citations - 4082
Joon S. Lee is an academic researcher from University of Pittsburgh. The author has contributed to research in topics: Coronary artery disease & Valve replacement. The author has an hindex of 30, co-authored 74 publications receiving 3421 citations.
Papers
More filters
Journal ArticleDOI
Intramyocardial, Autologous CD34+ Cell Therapy for Refractory Angina
Douglas W. Losordo,Timothy D. Henry,Charles J. Davidson,Joon S. Lee,Marco A. Costa,Theodore A. Bass,Farrell O. Mendelsohn,F. David Fortuin,Carl J. Pepine,Jay H. Traverse,David L. Amrani,Bruce M. Ewenstein,Norbert Riedel,Kenneth Story,Kerry Barker,Thomas J. Povsic,Robert A. Harrington,Richard A. Schatz +17 more
TL;DR: Patients with refractory angina who received intramyocardial injections of autologous CD34+ cells (105 cells/kg) experienced significant improvements in angina frequency and exercise tolerance.
Journal ArticleDOI
2-Year Outcomes in Patients Undergoing Surgical or Self-Expanding Transcatheter Aortic Valve Replacement
Michael J. Reardon,David H. Adams,Neal S. Kleiman,Steven J. Yakubov,Joseph S. Coselli,G. Michael Deeb,Thomas G. Gleason,Joon S. Lee,James B. Hermiller,Stan Chetcuti,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,Brijeshwar Maini,Mubashir Mumtaz,John V. Conte,Jon R. Resar,Vicken Aharonian,Thomas A. Pfeffer,Jae K. Oh,Hongyan Qiao,Jeffrey J. Popma +26 more
TL;DR: In patients with severe aortic stenosis who are at increased surgical risk, the higher rate of survival with a self-expanding TAVR compared with surgery was sustained at 2 years.
Journal ArticleDOI
3-Year Outcomes in High-Risk Patients Who Underwent Surgical or Transcatheter Aortic Valve Replacement
G. Michael Deeb,Michael J. Reardon,Stan Chetcuti,Himanshu J. Patel,P. Michael Grossman,Steven J. Yakubov,Neal S. Kleiman,Joseph S. Coselli,Thomas G. Gleason,Joon S. Lee,James B. Hermiller,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,Brijeshwar Maini,Mubashir Mumtaz,John V. Conte,Jon R. Resar,Vicken Aharonian,Thomas A. Pfeffer,Jae K. Oh,Hongyan Qiao,David H. Adams,Jeffrey J. Popma,CoreValve U.S. Pivotal High Risk Trial Clinical Investigators +29 more
TL;DR: Patients with severe aortic stenosis at increased risk for surgery had improved 3-year clinical outcomes after TAVR compared with surgery, and aorti valve hemodynamics were more favorable in TAVr patients without differences in structural valve deterioration.
Journal ArticleDOI
A comparison of bare-metal and drug-eluting stents for off-label indications.
Oscar C. Marroquin,Faith Selzer,Suresh Mulukutla,David O. Williams,Helen Vlachos,Robert L. Wilensky,Jean-Francois Tanguay,Elizabeth M. Holper,J. Dawn Abbott,Joon S. Lee,Conrad Smith,William D. Anderson,Sheryl F. Kelsey,Kevin E. Kip +13 more
TL;DR: The use of drug-eluting stents for off-label indications was not associated with an increased risk of death or myocardial infarction but was associated with a lower rate of repeat revascularization at 1 year, as compared with bare-metal stents.
Journal ArticleDOI
5-Year Outcomes of Self-Expanding Transcatheter Versus Surgical Aortic Valve Replacement in High-Risk Patients
Thomas G. Gleason,Michael J. Reardon,Jeffrey J. Popma,G. Michael Deeb,Steven J. Yakubov,Joon S. Lee,Neal S. Kleiman,Stan Chetcuti,James B. Hermiller,John Heiser,William Merhi,George L. Zorn,Peter Tadros,Newell Robinson,George Petrossian,G. Chad Hughes,J. Kevin Harrison,John V. Conte,Mubashir Mumtaz,Jae K. Oh,Jian Huang,David H. Adams,CoreValve U.S. Pivotal High Risk Trial Clinical Investigators +22 more
TL;DR: This study shows similar mid-term survival and stroke rates in high-risk patients following TAVR or SAVR, and suggests that valve reinterventions were uncommon.